Evidence mapPaperPMID 40565507Full record

ArticleGenes2025

The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles.

Robert Morris, Suguna Aishwarya Kuppa, Xinran Zhu, Kun Bu, Weiru Han, Feng Cheng

Abstract read
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Robert MorrisDepartment of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.
Suguna Aishwarya KuppaDepartment of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.ORCID 0009-0007-3438-9340
Xinran ZhuDepartment of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.
Kun BuDepartment of Mathematics & Statistics, College of Art and Science, University of South Florida, Tampa, FL 33620, USA.ORCID 0009-0006-9526-3023
Weiru HanDepartment of Mathematics & Statistics, College of Art and Science, University of South Florida, Tampa, FL 33620, USA.ORCID 0000-0002-6264-3090
Feng ChengDepartment of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.ORCID 0000-0003-3619-8090

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesBradycardia, an uncharacteristically low heart rate below 60 bpm, is a commonly reported adverse drug event (ADE) in individuals administered dexmedetomidine for sedation. Dexmedetomidine is frequently used as a sedative and analgesic for both intubated and non-intubated patients due to its low risk of respiratory depression. The purpose of this study was to further characterize the safety profile of dexmedetomidine using safety reports collected from the FDA Adverse Event Reporting System (FAERS) and transcriptomic data.

methodsAssociation rule mining was used to both identify additional ADEs that presented concurrently with bradycardia in patients sedated with dexmedetomidine, as well as to characterize potential drug-drug interactions (DDIs). Furthermore, public transcriptomic data were analyzed to identify differentially expressed genes that may elucidate the genetic drivers of elevated bradycardia risk in those administered dexmedetomidine.

resultsBradycardia was the most frequently reported ADE for individuals administered dexmedetomidine. Other cardiovascular-related ADEs commonly associated with bradycardia included syncope (lift = 4.711), loss of consciousness (lift = 3.997), cardiac arrest (lift = 2.850), and hypotension (lift = 2.770). Several possible DDIs were identified, including Lactated Ringer's solution (lift = 5.441), bupivacaine (lift = 2.984), and risperidone (lift = 2.434), which may elevate bradycardia risk. Finally, eight genes related to cardiac muscle contraction were identified as possible regulators of dexmedetomidine-induced bradycardia, including

conclusionsKey clinical takeaways include the co-presentation of multiple cardiovascular ADEs, including cardiac arrest, hypotension, and syncope, alongside dexmedetomidine-associated bradycardia. Furthermore, several possible DDIs with dexmedetomidine were also identified.

Indexed as

Adverse Drug Reaction Reporting SystemsBradycardiaDexmedetomidineHypnotics and SedativesTranscriptomeAnimalsDrug InteractionsFemaleGene Expression ProfilingHumansMaleUnited StatesUnited States Food and Drug AdministrationDexmedetomidineHypnotics and Sedativesassociation rulesbradycardiaDDIdexmedetomidinedrug interactionsFAERSpharmacovigilanceRNA-seq

Identifiers

PMID40565507
PMCPMC12191454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.